157 related articles for article (PubMed ID: 11750253)
1. Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker.
Roehrborn CG
Urology; 2001 Dec; 58(6 Suppl 1):55-63; discussion 63-4. PubMed ID: 11750253
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.
van Kerrebroeck P; Jardin A; Laval KU; van Cangh P
Eur Urol; 2000 Mar; 37(3):306-13. PubMed ID: 10720857
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial.
Roehrborn CG
Urology; 2001 Dec; 58(6):953-9. PubMed ID: 11744466
[TBL] [Abstract][Full Text] [Related]
4. First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia.
Marks LS; Roehrborn CG; Gittelman M; Kim D; Forrest J; Jacobs S
Urology; 2003 Nov; 62(5):888-93. PubMed ID: 14624914
[TBL] [Abstract][Full Text] [Related]
5. Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia.
McKeage K; Plosker GL
Drugs; 2002; 62(4):633-53. PubMed ID: 11893233
[TBL] [Abstract][Full Text] [Related]
6. Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
Elhilali MM
Expert Opin Pharmacother; 2006 Apr; 7(5):583-96. PubMed ID: 16553574
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study.
van Kerrebroec P; Jardin A; van Cangh P; Laval KU;
Eur Urol; 2002 Jan; 41(1):54-60; discussion 60-1. PubMed ID: 11999466
[TBL] [Abstract][Full Text] [Related]
8. Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Höfner K; Claes H; De Reijke TM; Folkestad B; Speakman MJ
Eur Urol; 1999 Oct; 36(4):335-41. PubMed ID: 10473995
[TBL] [Abstract][Full Text] [Related]
9. Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia.
Guay DR
Am J Geriatr Pharmacother; 2004 Mar; 2(1):14-23. PubMed ID: 15555475
[TBL] [Abstract][Full Text] [Related]
10. Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects.
MacDonald R; Wilt TJ
Urology; 2005 Oct; 66(4):780-8. PubMed ID: 16230138
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
Roehrborn CG; Van Kerrebroeck P; Nordling J
BJU Int; 2003 Aug; 92(3):257-61. PubMed ID: 12887479
[TBL] [Abstract][Full Text] [Related]
12. Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction.
Buzelin JM; Delauche-Cavallier MC; Roth S; Geffriaud-Ricouard C; Santoni JP
Br J Urol; 1997 Jun; 79(6):898-904; discussion 904-6. PubMed ID: 9202556
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Djavan B; Marberger M
Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
[TBL] [Abstract][Full Text] [Related]
14. Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia.
Lee M
Am J Health Syst Pharm; 2003 Jul; 60(14):1426-39. PubMed ID: 12892027
[TBL] [Abstract][Full Text] [Related]
15. Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia.
Kirby RS
Eur Urol; 1998; 33 Suppl 2():19-27. PubMed ID: 9556192
[TBL] [Abstract][Full Text] [Related]
16. Alfuzosin: a clinically uroselective alpha1-blocker.
Höfner K; Jonas U
World J Urol; 2002 Apr; 19(6):405-12. PubMed ID: 12022709
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group.
Buzelin JM; Roth S; Geffriaud-Ricouard C; Delauche-Cavallier MC
Eur Urol; 1997; 31(2):190-8. PubMed ID: 9076465
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
Nordling J
BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
[TBL] [Abstract][Full Text] [Related]
19. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.
Wilde MI; Fitton A; McTavish D
Drugs; 1993 Mar; 45(3):410-29. PubMed ID: 7682910
[TBL] [Abstract][Full Text] [Related]
20. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
Lowe FC
Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
